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Cells isolated from congenital melanocytic nevi and cultured in vitro have growth characteristics that resemble their pre-
malignant stage in situ. A serum-free, chemically defined medium has been developed that allows continuous growth of
established nevus cultures for up to several months. Like primary melanoma cells, nevus cells in high-calcium. containing
W489 medium require insulin for growth. In contrast to melanoma cells, nevus cells in serum-free medium require the
presence of a-melanocyte – stimulating hormone, which enhanced intracellular levels of cyclic adenosine monophosphate.
In contrast to the requirements of normal human melanocytes from newborn foreskin, congenital nevus cells grow with
less dependency on basic fibroblast growth factor (bFGF). Nevus cultures contain bFGF-like activity, and they express
bFGF mRNA. Nevic cells of compound nevi also express bFGF mRNA in situ but only in the junctional areas. These results
indicate that bFGF plays an important growth regulatory role for nevus cells in vitro and in vivo. J Invest Dermatol
100:281S–287S, 1993
Nevi are congenital or acquired hyperplastic melanocytic lesions
potentially capable of evolving into malignant melanoma. This evolution
has been observed in 1.1% of small congenital nevi and 6.3% of giant
congenital nevi. The proportion of melanoma cases associated with a
small congenital nevus has been reported as high as 14.9% [1]. Among
the acquired nevi, cells of the familiar dysplastic nevus syndrome
may have a high probability for malignant transformation [2,3]. Cultures
of common acquired and congenital nevi have an antigenic phenotype
similar to melanoma cells when tested with monoclonal antibodies
binding to cell-surface antigens [4–6]. Nevus cultures also grow
anchorage independently in soft agar, similar to primary melanoma cells
from early lesions, but they do not form tumors in athymic nude mice.
Nevus cells have a finite life span and do not spontaneously transform
in vitro; they have a diploid karyotype [7], but random abnormalities may
occur [8]. As demonstrated from these investigations, nevus cells in vitro
have properties that differ from both normal melanocytes and malignant
melanoma cells.
Melanocytic cells isolated from different stages of tumor development
reflect each stage of tumor progression in their in vitro requirements for
exogenous growth factors [9]. Normal melanocytes require several
supplements in a high-calcium-containing medium: insulin or insulin-
like growth factor-I (IGF-I); a-melanocyte -stimulating hormone (MSH) or
other compounds that increase intracellular levels of cyclic adenosine
monophosphate (cyclic AMP) (including follicle-stimulating hormone or
choleratoxin); the phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate
(TPA); and basic fibroblast growth factor (bFGF) [10]. In contrast, primary
melanoma cells of the vertical growth phase from biologically early
lesions require only IGF-I or insulin for continuous proliferation [11], and
primary melanoma cells from biologically late vertical growth phase
lesions and metastatic melanoma cells grow independently of these two
growth factors and any other mitogens [12].
In this study, we investigated the growth requirements for congenital
nevus cells as part of our long-term study of the molecular mechanisms of
melanoma development. When compared with normal melanocytes,
nevus cells present with an increased but heterogenous independence
from bFGF. bFGF-like activity is being synthesized, and nevus cells
in vitro and in situ express bFGF mRNA. At the same time, nevus cells
remain dependent on a-MSH, which acts by enhancing intracellular
levels of cyclic AMP, and on insulin (like primary melanoma cells).
Nevus cells, therefore, provide an ideal cell type to investigate the
mechanisms of autocrine and para-crine growth stimulation at inter-
mediate stages of tumor progression.
MATERIALS AND METHODS
Nevus Cell Culture Portions of congenital nevi, obtained from the Pigmented
Lesion Clinic and the Children0s Hospital of the University of Pennsylvania,
Philadelphia, were processed for histology and tissue culture, as previously
described [6]. The age of the donors ranged from 2 to 36 years. Ten of the
donors were younger than 10 years. The nevus samples were incubated
overnight at 4 1C in 0.25% trypsin in Hanks’ balanced salt solution without
Caþ þ and Mgþ þ and were supplemented with 20mM N-[2-hydroxyethyl]pi-
perazine-N0-[2-ethanesulfonic acid]. After this initial incubation, the epider-
mis was removed from the dermis, and the dermal surface was gently scraped
to obtain junctional cells. The epidermal sheet and the dermis were separately
digested for 3–5 h at 37 1C in an enzymatic mixture of 0.05% collagenase type
1,0.1% hyaluronidase (both from Sigma Chemical Co., St. Louis, MO) and
1.25U/ml dispase (neutral protease grade II; Boehringer Mannheim,
Indianapolis, IN) for the dermis; and hyaluronidase, dispase, and 0.033%
ethylenediaminetetraacetic acid (EDTA) for the epidermis. Cells obtained
from the epidermal, junctional, and dermal components of each lesion were
then seeded separately in complete culture medium, consisting of W489
medium [10] supplemented with 5 mg/ml insulin, 5 ng/ml epidermal growth
factor (Collaborative Research, Bedford, MA), 10 ng/ml TPA (Chemicals for
Cancer Research, Canhassen, MN) [13], 2% fetal calf serum, and 40mg/ml of
an extract of bovine pituitary glands (Pel Freeze, Roger, AR) [6]. A chemically
defined serum-free medium was developed as described previously for
normal melanocytes [10]. The following supplements were tested in
different combinations in W489 medium: cholera toxin A and B subunits
(List Biological Labs, Campbell, CA) and bFGF [13] and epidermal growth
factor, both from Collaborative Research. Insulin, human follicle-stimulating
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hormone, forskolin, and ceruloplasmin were from Sigma, and synthetic
a-MSH was from Bachem Fine Chemicals (Torrance, CA). Calcium
concentrations in the medium were tested using MCDB 153 medium without
L 15 medium. To improve cell attachment, plastic tissue culture plates were
pretreated for 1 h at 37 1C with 1% gelatin in physiologic saline solution. The
coating medium was completely removed before seeding cells.
Growth Assays for Nevus Cells For growth assays, cell lines established in
serum-containing medium were seeded into duplicate or triplicate wells of
24-well plates at a concentration of 1–2 104 cells/cm2. At different times and
up to between 16 and 21 d, cells were washed with modified Hanks’
balanced salt solution, detached by trypsinization, and counted in a Coulter
counter.
Heparin–Sepharose Chromatography of Nevus Extracts to Test for bFGF-Like
Activity Adherent cells (approximately 1 108/cell line) were detached,
washed, pelleted, snap-frozen, and thawed three times, and lysed using 2ml
of lysis buffer containing 0.6M NaCl, 10mM Tris (hydroxymethyl) amino-
methane (Tris) HCl, and 12mM [3-(C3-cholamidopropyl)-dimethylam-mon-
ia]-2-hydroxy-l -propane sulfonate (CHAPSO) (Pierce, Rock-ford, IL), pH 7.0.
The cell lysate was sonicated on ice for 5min and diluted with an additional
30ml lysis buffer. Lysates were then passed through a heparin-Sepharose
column (bed volume 10ml; Pharmacia, Uppsala, Sweden) [14]. Heparin-
binding proteins were eluted with NaCl solutions (pH 7.0) of increasing
molarity ranging between 0.6 and 2.0M. Eluates were dialyzed extensively
against 0.8mM CHAPSO in double distil H2O, lyophilized, and stored at
70 1C until use. Growth assays were performed on Swiss 3T3 fibroblasts by
measuring incorporation of [methyl-3H]thymidine for 8 h (0.2mCi/well) and
on melanocytic cells by counting cell numbers on days 1–14.
mRNA Detection of bFGF by Reverse Transcriptase-Polymerase Chain
Reaction Total RNA was extracted from subconfluent cell cultures by the
guanidinium thiocyanate-phenol-chloroform extraction method [15] using
RNA-sol (Cinna/Biotecx Laboratories, Houston, TX). cDNA was prepared
from total RNA according to the manufacturer’s protocol using Moloney
murine leukemia virus RNase H reverse transcriptase (Bethesda Research
Laboratories, Gaithersburg, MD). Amplification by polymerase chain reaction
(PCR) was performed as previously described [16]. Briefly, 1.25 ml of each
cDNA mixture was added to a total of 25ml reaction mixture containing
2.5ml 10PCR buffer [100mM Tris HCl (pH 8.3), 500mM KCl, 15mM
MgCl2,0.1% gelatin (w/v), 0.1% Tween 20,0.1% nonidet 40 (IBI, New Haven,
CT)]; 200mM each of deoxy adenosine triphosphate, deoxycytosine triphos-
phate, deoxy thymidine triphosphate, deoxy guanosine triphosphate (Boeh-
ringer Mannheim); 25 ng of each priming oligomer; and 1.0 U of Taq
polymerase (IBI). DNA amplification was performed using a DNA thermal
cycler (Perkin Elmer, Norwalk, CT). Cycle conditions were the following: (1)
for the first cycle, 94 1C for 2min, 51 1C (bFGF) or 55 1C (b-actin) for 1min
and 30 s, 72 1C for 1min and 30 s; and (2) from the second to the 35th cycle,
94 1C for 50 s, 51 1C (bFGF) or 55 1C (b-actin) for 1min and 30 s, 72 1C for
1min and 30 s, and 10min at 72 1C after the last cycle. Annealing
temperatures were determined using the OLIGO program [17]. Electrophoresis
of 10 ml of reaction mixture on a 2% Ultrapure agarose gel containing
ethidium bromide was performed to evaluate amplification and size of
fragments generated. Oligonu-cleotide primers were synthesized on a
Biosearch 8700 (Milligen Biosearch, Burlington, MA) DNA synthesizer.





(The sequence of the bFGF oligonucleotide primers was kindly provided by
Dr. A.P. Albino, New York, NY.) The b-actin [18] and bFGF [19] primers were
chosen to be on different exons of the respective genes.
Southern hybridization analysis of the PCR amplification products was
done as previously described [20]. A 25-mer oligonucleotide was designed
using the OLIGO software for hybridization of the bFGF PCR products:
50-TTACGGATGAGTGTTTCTTTTTTGA-30.
The oligonucleotide was chosen to be in the amplified sequence. The
oligonucleotides were labeled using a BRL. 50DNA terminus labeling kit
(Bethesda Research Laboratories Life Technologies, Gaithersburg, MD). The
membrane was prehybridized at 59.5 1C for 6 h in 6 SSC, 0.5% sodium
dodecyl sulfate (SDS), 5Denhard’s solution, and 100 mg/ml salmon sperm
DNA. The hybridization was done at 59.5 1C overnight at 6 SSC, 0.5% SDS,
and 100 m/ml salmon sperm DNA. Posthybridization washings were done for
2min each: twice in 2 SSCþ0.1% SDS, twice in 2 SSCþ 0.5% SDS, once
in 0.1 SSCþ 0.5% SDS at room temperature, and once in 0.1 SSCþ 0.5%
SDS at 59.5 1C. The membrane was exposed to a Kodak X-AR film for 24 h.
In situ Hybridization Technique for bFGF mRNA Detection Tissue blocks of
common acquired compound nevi were fixed in neutral formaldehyde and
embedded in paraffin. Five-micrometer–thick sections were prepared and
mounted on poly-L-lysine – coated (Sigma) glass slides. After hydrating
through a series of graded ethanol baths, tissue samples were permeabilized
with HCl (0.2 N, 30min) and digested with proteinase K [1mg/ml from
Boehringer Mannheim in 10mM Tris (pH 7.4), 2mM CaCl2 in d H2O] at 37 1C
for 30min. The slides were then washed with 2 SSC (300mM NaCl, 30mM
sodium citrate, pH 7.0) and air dried. Hybridization was carried out at 50 1C
for 24–48h using the 1.4-kDa sense and antisense bFGF cDNA probes [19].
Following hybridization, slides were washed in chloroform (2 5min) and
wash solution [2 SSC, 45% formaldehyde, 10mM Tris (pH 7.4), 1mM EDTA
(pH 8.0), in distil H2O] for 212 h and finally dehydrated in graded ethanol
containing 0.3M ammonium acetate. Autoradiography was carried out using
NTB2 nuclear emulsion (Eastman Kodak, Rochester, NY), diluted with 0.6M
ammonium acetate. Slides were exposed for 7–10 d at 4 1C, then they were
developed in D19, fixed in Kodak fixer (Eastman Kodak), and counterstained
with hematoxylin and eosin. Control slides were treated with RNase A and
RNase Tl (100 mg/ml and 1mg/ml, respectively; both from Boehringer
Mannheim) at 37 1C for 15min. Probes were labeled with 32P by nick
translation for up to 1108 cpm/Figure For semiquantitative evaluation, a
numerical grading system was used [20]: 1 þ was approximately 5 grains/cell
over background (low expression); 2þ was 5–10 grains/cell over background
(medium expression); and 3þwas more than 10 grains/cell over background
(high expression).
Cyclic AMP Determination Human nevus cells were grown in 75-cm2 flasks
at 8 105 cells/flask. Fifteen and 30min after addition of a-MSH (50 ng/ml) or
cholera toxin (50 ng/ml), medium was aspirated, and flasks were flooded with
1ml cold ethanol containing 1 N HCl (20 1C). After standing for 1 h at
20 1C, cells were scraped and pelleted in a microcentrifuge at 4 1C. The
pellets were dried and reconstituted with 250 ml of acetate buffer. The cyclic
AMP level was determined with a commercial radioimmuno-assay kit
(Biomedical Technologies Inc., Stoughton, MA) using a nonacetylation step
and 125I-succinyl- cyclic AMP as tracer. The results were expressed as percent
of controls.
RESULTS
Growth of Nevus Cells in Serum-Free Medium Twenty nevus cell lines
isolated from 15 lesions were established in serum-containing medium
and then adapted to a chemically defined serum-free medium consisting
of W489 medium supplemented with insulin, bFGF, TPA, and a-MSH.
This medium was not suitable for establishing primary cultures, but after
the cells were passaged one or two times, the medium supported growth
in all but one cell line. None of the supplements supported nevus cell
growth if added individually. The response of nevus cells in deletion
experiments showed two patterns (Fig 1). (1) Cell growth decreased
consistently after withdrawal of a-MSH and TPA in all nevus cultures
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tested. Deletion of insulin had a similar effect, but because insulin of IGF-
I is essential for growth of even malignant primary melanoma cells [11],
this result was to be expected. (2) Minimal response of nevus cells was
seen when bFGF was deleted from medium. The response of cultures
from different nevi to exogenous bFGF was heterogenous, varying
between complete dependence and independence.
Nevus cell lines that were continuously maintained in serum-free
medium showed a slower growth rate than those grown in the presence
of serum. The population-doubling times varied between 5 and 30 d for
cell lines in serum-free medium and between 4 and 14 d in serum- and
pituitary extract-containing medium. Cell lines from the three different
skin components – epidermis, epidermal – dermal junction, and dermis –
did not differ in growth rate, and there was no correlation between the
degree of cell proliferation and donor age. Fourteen cell lines were
passaged 3–16 times during a 7-month period, whereas five could be
maintained in culture for several months but did not divide. There were
also no morphologic differences between nevus cells grown in serum-
free or serum-containing medium (Fig 2).
Effect of a-MSH on Nevus Cells The optimum concentration of a-MSH in
stimulation experiments was at 10 ng/ml in all six cultures tested. One
example is shown in Fig 3. As little as 0.1 ng/ml of a-MSH stimulated
proliferation significantly (Po0.001 in Student t test). a-MSH in medium
containing serum and pituitary extract had no effect on nevus cell growth
(not shown). a-MSH also had no effect on the growth of six primary and
metastatic melanoma cell lines maintained in serum-containing or
serum-free medium (not shown). Follicle-stimulating hormone, cholera
toxin, ceruloplasmin, and forskolin, all of which can replace a-MSH as
mitogens for normal melanocytes [10], did not significantly stimulate
proliferation of nevus cells (not shown).
a-MSH increased the levels of cyclic AMP in nevus cells (Fig 4). After
15-min incubation with a-MSH, nevus cells increased their intracellular
cyclic AMP level twofold compared with the control.
The same nevus cells treated with cholera toxin (the positive
control agent) showed no significant increase. By contrast, after 30min
cholera toxin increased the cyclic AMP level, but there was no longer
an increased cyclic AMP level in nevus cells that were incubated with
a-MSH.
Effect of Calcium Concentration in Medium Growth of nevus cells in
serum-free, chemically defined medium depended, like that of melano-
cytes [10], on the calcium concentration in medium. MCDB 153 medium
supplemented with insulin, bFGF, a-MSH, and TPA supported nevus cell
growth only if calcium was added at concentrations of more than 0.8mM,
with an optimum at 2.0mM (Fig 5). A 0.03-mM concentration of calcium
in the medium is optimal for growth of non-differentiating keratinocytes
[19], but at that concentration nevus cell numbers had decreased by 70%
on day 17 compared with day 1. The attachment of nevus cells on day 1
in medium with 0.03mM calcium was also 20% lower than in 2.0mM
calcium-containing medium. Calcium in medium at 3.0mM or more was
less stimulatory than at 2mM (not shown).
Figure 1. Growth of WM 1559B-BL nevus cells in different serum-free media
(SF): W489 medium supplemented with insulin, bFGF, TPA, and a-MSH
(complete SF); serum-free medium depleted of all growth factors (protein-free
medium, PF) or of insulin only (SF-[minus] insulin), TPA only (SF-TPA), a-MSH
only (SF-MSH), and bFGF only (SF-FGF). Error bars, standard deviation of
triplicate samples.
Figure 2. Nevus cell lines isolated from congenital nevi and grown in serum-
containing (A) and serum-free medium (B): 1, epidermal component (cell line
WM 1559 B-E); 2, junctional component (cell line WM 1559 B-BL); and 3,
dermal component (cell line WM 1555-D). No evident morphologic
differences could be detected between cells maintained in the presence or
absence of serum.
Figure 3. Effects of different concentrations of a-MSH on nevus cell
proliferation. Nevus cells were seeded in protein-free medium (PF) or in
complete serum-free medium (SF) containing different concentrations of
a-MSH: none [SF (no MSH)]; 0.1 ng/ml (SF -I- MSH 0.1); 1 ng/ml (SFþMSH
1); 10 ng/ml (SFþMSH 10); or 100 ng/ml (SFþMSH 100). Cell number was
determined on days 1, 5, 10, and 16. Error bars, standard deviation of
triplicate samples.
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bFGF in Nevus Cells bFGF-like activity was detected in extracts of nevus
cells. 2M NaCl eluates from heparin-Sepharose columns loaded with
lysates of pooled WM 1555D and WM 1559 BL nevus cell lines
increased [3H]thymidine incorporation into Swiss 3T3 indicator cells
15.6 times, whereas pooled lysates of five melanocyte cultures were not
stimulatory. Extracts of six melanoma cultures, which were included in
these studies for controls, had a growth-stimulating effect for 3T3 cells
between 2.4 and 20.0 times.
bFGF-specific mRNA molecules were detected by reverse transcrip-
tase –PCR in all three nevus cell lines tested and in a melanoma cell line
included as positive control (Figs 6 and 7). The amplification yielded the
predicted 239-bp DNA fragment. Labeled bFGF-specific oligonucleo-
tides hybridized specifically with the amplified bFGF DNA (Fig 8, lanes
1–4). The probe did not hybridize to the control b-actin DNA nor to Hae
III-digested PhiX 174-phage DNA (molecular weight marker).
bFGF mRNA could not be detected in the majority of cells in
common acquired compound nevi. Using in situ hybridization, bFGF
mRNA could not be detected in the vast majority of cells in common
acquired compound nevi. In four of five specimens, however, high signal
intensity (3þ ) was observed in junctional nevus cells (Fig 9). Dermal
nevus cells were negative, and only scattered fibroblasts tested positive
for bFGF message. A low (1 þ ) signal intensity was observed in basal
and suprabasal keratinocytes but not in more differentiated layers of the
epidermis. Signal intensities within the basal layer of the epidermis were
Figure 4. Increase in levels of cyclic AMP after treatment of nevus cell line
WM 1905 with 50 ng/ml a-MSH or 50 ng/ml cholera toxin for 15 and 30min.
The results were the average of duplicates.
Figure 5. Nevus cell growth in complete serum-free medium but with
different calcium concentrations. Results are expressed as percentage of cell
growth after 17 d.
Figure 6. PCR using b-actin-specific primers. Size of the amplified fragment
was 540 bp; 2% agarose gel was stained with ethidium bromide. (A) Lane 1,
melanoma WM 164 cDNA (positive control for PCR); lane 2, melanoma WM
164 mRNA (positive control for restriction transcriptase-PCR); lane 3,
congenital nevus WM 1954B total RNA; lane 4, Hae Ill-di-gested PhiX 174
phage DNA. (B) lane 1, melanoma WM 164 mRNA; lane 2, congenital nevus
WM 1964 total RNA; lane 3, congenital nevus WM 2029 total RNA; lanes 4
and 5, blank; lane 6, Hae Ill-digested PhiX 174 phage DNA.
Figure 7. PCR using bFGF specific primers. The 2% agarose gel was stained
with ethidium bromide. Lane 1, nevus WM 1964 total RNA; lane 2, nevus
WM 2029 total RNA; lane 3, nevus WM 1954B total RNA; lane 4, melanoma
WM 164 mRNA; lane 5, b-actin-specific amplified product for WM 164
melanoma; lane 6, Hae Ill-digested PhiX 174 phage DNA.
Figure 8. Twenty-four hour autoradiograph of Southern blot hybridized with
end-labeled bFGF specific primer. Lane 1, nevus WM 1964; lane 2, nevus
WM 2029; lane 3, nevus WM 1954B; lane 4, melanoma WM 164; lane 5,
b-actin specific product amplified from WM 164 melanoma; lane 6, Hae Ill-
digested PtuX 174 phage DNA.
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also evenly distributed; thus, we assumed that epidermal melanocytes do
not have higher signal intensities than surrounding basal keratinocytes.
DISCUSSION
Nevus cells in culture reflect their non-malignant phenotype in situ [4,6].
Nevus cells share a similar morphology and antigen expression with
melanocytes, and, like normal melanocytes, nevus cells require several
exogenous mitogens, such as a-MSH and TPA, and high calcium
concentrations for their continuous growth in culture. The serum-free
medium developed for nevus cells in this study is similar to that
developed for normal melanocytes [10]; however, nevus cells differ from
normal melanocytes in several respects. Melanocytes from different
newborn donors adapt to in vitro conditions with predictable uniformity,
whereas nevus cells constitute a heterogeneous cell population,
reflecting their relative genetic instability. Derived from histologically
different lesions and from donors of different ages, they generate cultures
that often vary in morphology, growth characteristics, and life span. This
heterogeneity was particularly evident in serum-free medium. Some cell
lines were capable of merely surviving in serum-free medium for
extended periods of time (without dividing), whereas others went through
numerous cell doublings. Unlike newborn melanocytes [10], nevus cell
lines (14 in this study) did not require exogenous bFGF to proliferate. We
could demonstrate bFGF-like activity and bFGF mRNA in extracts of
cultured nevus cells. The relative independence of nevus cells from bFGF
in culture medium and the synthesis of bFGF by these cells suggest that
Figure 9. In situ hybridization to bFGF mRNA in compound nevus. (A) Low magnification photomicrograph shows high expression of bFGF mRNA along the
junctional zone of nevus (arrowheads). Note that surrounding normal skin has low mRNA expression (small arrows). (B and C) Higher power fields of same
lesion. Note abundant mRNA expression of junctional nevus cells. (D) Dermal nevus cells from the same origin show no expression of bFGF mRNA. bFGF is
expressed only by dermal fibroblasts (arrowheads).
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this growth factor is synthesized even by non-malignant melanocytic
cells. Melanoma cells were recently shown to produce bFGF as an
autocrine factor [21,22]. In situ expression of bFGF mRNA in nevic
lesions was mostly confined to junctional areas of lesions. Normal
epidermis showed little bFGF reactivity when tested with monoclonal
antibodies for protein expression [23] or by in situ hybridization for
mRNA expression [24]. It is likely that cultured nevus cells, like
melanoma cells, produce bFGF for autocrine stimulation, which could
provide a growth advantage for nevus cells. The role of bFGF in situ may
be more complex (see [25,26] for reviews). For example, bFGF may
enhance the activity of a variety of cellular products such as plasminogen
activators. The confinement of bFGF mRNA to junctional areas of
compound nevi may point to a role for bFGF in the migration of nevus
cells through basement membrane zones.
Both intracellular and extracellular calcium concentrations have a
profound effect on cell growth [27,28], although the response is
heterogenous among different types of cells. Calcium concentrations
ranging between 0.03 and 2mM have a slight effect on the growth of
murine B16 melanoma cells [27] and human melanoma cells (our
unpublished data) in vitro. In contrast, in this study we showed that the
growth of nevus cells, like normal human melanocytes [10], is calcium
dependent. Measurement of intracellular calcium in response to different
extracellular calcium concentrations and evaluation of calcium channel
expression on melanocytic cells are being investigated.
In contrast to normal melanocytes from newborn foreskin [10],
congenital nevus cells cannot be stimulated in serum-free medium by
agents that increase the intracellular levels of cyclic AMP (follicle-
stimulating hormone, cholera toxin, or forskolin). The mitogenic effect of
a-MSH on normal melanocytes can be seen only in chemically defined
medium [10] but not in serum-containing medium [29]. Similarly, a-MSH
promotes neurite outgrowth in bovine chromamn cells in serum-free
medium but, apparently, not in serum-containing medium, indicating that
serum inhibits or masks the activity of a-MSH. Melanocytic cells,
particularly of murine origin, have long been known to be the targets of
a-MSH [10,30–34]. Characterization of receptors for a-MSH on both human
and murine melanoma cells were recently described [35,36]. Increased
intracellular cyclic AMP level following the treatments of melanocytic cells
with a-MSH, phosphodiesterase inhibitors, and other agents have profound
physiologic effects on these cells [37–40]. In this study, we showed that
a-MSH increased intracellular cyclic AMP concentration in cultured human
nevus cells. This result suggested that human nevus cells, like the normal
human melanocytes and melanoma cells, may respond to a-MSH, and the
biologic effects of a-MSH on nevus cells, such as growth stimulation, may
be associated with increased cyclic AMP level. The different kinetics of
cyclic AMP level in nevus cells treated with a-MSH or with cholera toxin
may reflect the different mechanisms of action of both agents. The observed
differences between nevus cells and newborn foreskin melanocytes are
probably not related to body sites, because we have previously cultured
adult melanocytes from different parts of the body, and the biologic
characteristics are similar to newborn foreskin melanocytes, except that
adult cells have a shorter life span (M. Herlyn, unpublished observations).
Nevus cells appear to be one step closer than normal melanocytes in
developing growth autonomy that is characteristic for malignant cells.
On the other hand, the differences in growth requirements for a-MSH
between nevus and primary melanoma cells demonstrate the non-
malignant nature of nevus cells. On the other hand, the synthesis of bFGF
by nevus cells but not by normal melanocytes demonstrates their
difference from melanocytes and indicates the premalignant nature of
nevus cells. These data may lend further support to the hypothesis that
nevi represent an intermediate stage of tumor progression toward
melanoma. Further studies are needed to investigate the mechanisms of
activation of growth-factor synthesis, particularly bFGF, in nevus cells
and its role in nevus invasion into the dermal components of the skin.
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